Join Faraday Pharmaceuticals, Inc. for a KOL webinar on Tues. July 30 at 11am ET with Dr. Cheerag Shirodaria (Oxford University Hospitals), Dr. Marc Bonaca (University of Colorado Anschutz), and Dr. Antonio Gutierrez (Duke University Hospital and Durham VA Medical Center), who will discuss the unmet need and current treatment landscape in preventing ischemia-reperfusion injury and highlight the effects of STEMI on heart failure and other patient outcomes. Register here: https://bit.ly/4eXHjro
LifeSci Advisors, LLC
Financial Services
New York, New York 14,757 followers
Accelerating Innovations In Life Science.
About us
LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences field with a comprehensive solution to investor communications and outreach. Our services are designed to increase our clients’ visibility within the investment community and to educate investors about the opportunity. We strive to effectively communicate each clients’ unique value proposition, building momentum for the investment. We begin with deep due diligence as we partner with each client to gain an unparalleled level of understanding of their business and the opportunities they are addressing. This in-depth knowledge allows us to be able to provide each client partner with thoughtful recommendations related to corporate communications, investor outreach, and capital markets planning. Our strategies and actions are specifically tailored to help each client achieve their investor relations goals.
- Website
-
http://www.lifesciadvisors.com
External link for LifeSci Advisors, LLC
- Industry
- Financial Services
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2009
- Specialties
- Investor Relations
Locations
-
Primary
250 W 55th St
#3401
New York, New York 10019, US
Employees at LifeSci Advisors, LLC
Updates
-
Join DiaMedica Therapeutics Inc. (#DMAC) for a virtual KOL event on Mon. July 29 at 10am ET featuring Prof. Catherine Cluver, MD, PhD (Stellenbosch University), Prof. Stephen Tong, MD, PhD (The University of Melbourne), and Prof. Susan Walker, MD, PhD (The University of Melbourne) who will discuss the unmet need and current treatment landscape for preeclampsia (PE), a life-threatening pregnancy associated vascular disorder with no approved therapeutics. Register here: https://bit.ly/4cZir0A
-
ICYMI: Tune into the replay of the virtual KOL event hosted by Purple Biotech (#PPBT) featuring Michael Cecchini, MD (Yale School of Medicine) and E. Gabriela Chiorean, MD (Fred Hutchinson Cancer Center, University of Washington School of Medicine), who discuss the positive interim data from the Phase 2 study of CM24, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard of care chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (#PDAC). Watch here: https://bit.ly/3Wgzo14
-
Join CervoMed (#CRVO) for a virtual KOL event on Tues. July 23 at 10am ET to discuss neflamapimod for dementia with Lewy Bodies, featuring John-Paul Taylor, MBBS (hons), MRCPsych, PhD (Newcastle University) and Ralph A. Nixon, MD, PhD (New York University Grossman School of Medicine). Register here: https://bit.ly/3zFoEAA
-
Join Aligos Therapeutics (#ALGS) for a virtual KOL event on Thurs. July 18 at 3pm ET featuring Mark Sulkowski, MD (Johns Hopkins University School of Medicine), who will join company management to review positive Phase 1b data from the ongoing ALG-000184 clinical study presented at #EASL2024. Register: https://bit.ly/3WrdZ5D
-
Join Biora Therapeutics (#BIOR) for a virtual KOL event on Weds. July 17 at 2pm ET featuring Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai) and Brian Feagan, MD, FRCPC (Schulich School of Medicine & Dentistry at the University of Western Ontario), who will discuss the unmet need and current treatment landscape for patients with ulcerative colitis (UC), as well as the value of colonic drug delivery for improving efficacy. Register here: https://bit.ly/3S0bWCG
-
Join Purple Biotech (#PPBT) for a virtual KOL event on Thurs. July 11 at 10:30am ET featuring Michael Cecchini, MD (Yale School of Medicine) and E. Gabriela Chiorean, MD (Fred Hutchinson Cancer Center, University of Washington School of Medicine), who will discuss the positive interim data from the Phase 2 study of CM24, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard of care chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (#PDAC). Register here: https://bit.ly/3Wgzo14
-
Join Arrowhead Pharmaceuticals (#ARWR) for Part III of its Summer Series of R&D webinars on Tues. July 16 at 2pm ET featuring Matthias A. Salathe, MD (University of Kansas Medical Center) to provide updates on its key pulmonary programs in Phase 1/2 development: ARO-RAGE, ARO-MMP7, and ARO-MUC5AC. Register here: https://bit.ly/3Wg2Zb5
-
Join FibroGen, Inc. (#FGEN) for Part II of a virtual KOL investor event series on Wed. June 26 at 10am et featuring Rahul Aggarwal, MD (University of California San Francisco), who will discuss the unmet need and evolving treatment landscape for prostate cancer, as well as the clinical development program for FG-3246, a CD46 targeting antibody-drug conjugate (ADC) with first-in-class potential for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Register here: https://bit.ly/45zUaMl
-
Join us this Wednesday, June 26 at 1pm ET for the latest in our "Lunch with LifeSci" series, where we will interview Todd Davis, CEO of Ligand Pharmaceuticals (#LGND) to get an inside look at the biopharmaceutical royalty aggregator and its impressive portfolio. Register now: https://bit.ly/3xw9Ao2